Editas Medicine Inc (NASDAQ: EDIT) is 14.96% higher on its value in year-to-date trading and has touched a low of $1.12 and a high of $8.59 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The EDIT stock was last observed hovering at around $1.37 in the last trading session, with the day’s gains setting it 0.09%.
Currently trading at $1.46, the stock is -19.36% and -2.74% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.67 million and changing 6.57% at the moment leaves the stock -54.06% off its SMA200. EDIT registered -83.04% loss for a year compared to 6-month loss of -61.38%. The firm has a 50-day simple moving average (SMA 50) of $1.5012 and a 200-day simple moving average (SMA200) of $3.1781.
The stock witnessed a 22.69% gain in the last 1 month and extending the period to 3 months gives it a -30.48%, and is -15.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.69% over the week and 19.86% over the month.
Editas Medicine Inc (EDIT) has around 246 employees, a market worth around $121.15M and $32.31M in sales. Profit margin for the company is -733.74%. Distance from 52-week low is 30.36% and -82.99% from its 52-week high. The company has generated returns on investments over the last 12 months (-153.31%).
with sales reaching $873.44k over the same period.The EPS is expected to grow by 48.61% this year, but quarterly earnings will post -60.93% year-over-year. Quarterly sales are estimated to shrink -23.04% in year-over-year returns.
Editas Medicine Inc (EDIT) Top Institutional Holders
267.0 institutions hold shares in Editas Medicine Inc (EDIT), with institutional investors hold 66.34% of the company’s shares. The shares outstanding are 82.73M, and float is at 82.23M with Short Float at 16.74%. Institutions hold 66.13% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 8.03 million shares valued at $37.51 million. The investor’s holdings represent 9.8032% of the EDIT Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 7.78 million shares valued at $36.34 million to account for 9.498 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 6.0 million shares representing 7.2895% and valued at over $28.02 million, while STATE STREET CORP holds 5.5776 of the shares totaling 4.59 million with a market value of $21.44 million.
Editas Medicine Inc (EDIT) Insider Activity
The most recent transaction is an insider sale by Lucera Erick, the company’s EVP, CHIEF FINANCIAL OFFICER. SEC filings show that Lucera Erick sold 4,109 shares of the company’s common stock on Mar 04 ’25 at a price of $1.71 per share for a total of $7030.0. Following the sale, the insider now owns 0.11 million shares.
Editas Medicine Inc disclosed in a document filed with the SEC on Mar 04 ’25 that O’Neill Gilmore Neil (CEO) sold a total of 16,632 shares of the company’s common stock. The trade occurred on Mar 04 ’25 and was made at $1.71 per share for $28452.0. Following the transaction, the insider now directly holds 0.3 million shares of the EDIT stock.
Still, SEC filings show that on Mar 04 ’25, Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) disposed off 2,891 shares at an average price of $1.71 for $4946.0. The insider now directly holds 70,245 shares of Editas Medicine Inc (EDIT).
